GLP-1s

R&D

Big promises, hard work: What 2026 will demand from pharma

Eloise McLennan looks at a set of signals areas where pressure is building and 2026 looks set to demand more clarity, discipline, and follow-through.

R&D

Unlocking the future of obesity treatment

Obesity is more than a number on the scale, it’s a complex, malignant disease linked to diabetes, cardiovascular conditions, and even certain cancers.

R&D

GLP-1s in CKD: Evidence, market leadership, and key insights...

At ASN Kidney Week 2025, Glucagon-like peptide-1 (GLP-1) receptor agonists moved firmly into the nephrology spotlight.

R&D

pharmaphorum podcast Episode 227, Punit Dhillon, Skye Bioscience

On CB1s as an alternative to GLP-1s, with Punit Dhillon

In a new pharmaphorum podcast, Punit Dhillon, CEO of Skye Bioscience, discusses CB1 inhibitor antibodies in the obesity space.

R&D

pharmaphorum podcast Episode 221, Sandeep Kulkarni, Tourmaline Bio

On inflammation, heart health, and GLP-1 possibilities, with...

Sandeep Kulkarni, CEO of Tourmaline Bio, discusses inflammation, & the impact of AI and GLP-1s on cardiology clinical trials and drug development.

R&D

Global pharmaceutical market projections through 2030

Global pharmaceutical market projections through 2030, with Norstella's Daniel Chancellor.